137 related articles for article (PubMed ID: 31110518)
1. Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
Bronte G; Rocca A; Ravaioli S; Scarpi E; Bonafè M; Puccetti M; Maltoni R; Andreis D; Martinelli G; Bravaccini S
J Oncol; 2019; 2019():1393505. PubMed ID: 31110518
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
Bronte G; Rocca A; Ravaioli S; Puccetti M; Tumedei MM; Scarpi E; Andreis D; Maltoni R; Sarti S; Cecconetto L; Fedeli A; Pietri E; De Simone V; Asioli S; Amadori D; Bravaccini S
BMC Cancer; 2018 Mar; 18(1):348. PubMed ID: 29587674
[TBL] [Abstract][Full Text] [Related]
3. Role of androgen receptor expression in early stage ER+/PgR-/HER2- breast cancer.
Tagliaferri B; Quaquarini E; Palumbo R; Balletti E; Presti D; Malovini A; Agozzino M; Teragni CM; Terzoni A; Bernardo A; Villani L; Sottotetti F
Ther Adv Med Oncol; 2020; 12():1758835920958355. PubMed ID: 32994808
[TBL] [Abstract][Full Text] [Related]
4. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
[No Abstract] [Full Text] [Related]
5. The role of the AR/ER ratio in ER-positive breast cancer patients.
Rangel N; Rondon-Lagos M; Annaratone L; Osella-Abate S; Metovic J; Mano MP; Bertero L; Cassoni P; Sapino A; Castellano I
Endocr Relat Cancer; 2018 Mar; 25(3):163-172. PubMed ID: 29386247
[TBL] [Abstract][Full Text] [Related]
6. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Kensler KH; Regan MM; Heng YJ; Baker GM; Pyle ME; Schnitt SJ; Hazra A; Kammler R; Thürlimann B; Colleoni M; Viale G; Brown M; Tamimi RM
Breast Cancer Res; 2019 Feb; 21(1):30. PubMed ID: 30795773
[TBL] [Abstract][Full Text] [Related]
8. Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer.
Prabhu JS; Korlimarla A; Rajarajan S; Alexander A; Anupama C; Ramesh R; Srinath B; Sridhar TS
Cancer Res; 2021 Feb; 81(4 Suppl):. PubMed ID: 34421401
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up.
Mauri FA; Maisonneuve P; Caffo O; Veronese S; Aldovini D; Ferrero S; Cozzaglio F; Dalla Palma P; Galligioni E; Barbareschi M
Int J Oncol; 1999 Dec; 15(6):1137-47. PubMed ID: 10568820
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.
Alexieva-Figusch J; Van Putten WL; Blankenstein MA; Blonk-Van Der Wijst J; Klijn JG
Cancer; 1988 Feb; 61(4):758-68. PubMed ID: 3338038
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.
Erdem GU; Altundag K; Ozdemir NY; Sahin S; Demirci NS; Karatas F; Bozkaya Y; Aytekin A; Tasdemir V; Aslan AC; Sever AR; Zengin N
J BUON; 2017; 22(2):365-376. PubMed ID: 28534357
[TBL] [Abstract][Full Text] [Related]
14. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis.
Qu Q; Mao Y; Fei XC; Shen KW
PLoS One; 2013; 8(12):e82650. PubMed ID: 24324816
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
16. Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer.
Agrawal A; Ziolkowski P; Grzebieniak Z; Jelen M; Bobinski P; Agrawal S
Appl Immunohistochem Mol Morphol; 2016 Sep; 24(8):550-5. PubMed ID: 26230371
[TBL] [Abstract][Full Text] [Related]
17. Steroid hormone receptors and clinical usefulness in human breast cancer.
Nomura Y; Yamagata J; Takenaka K; Tashiro H
Cancer; 1980 Dec; 46(12 Suppl):2880-3. PubMed ID: 7448732
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes.
Orrù S; Pascariello E; Sotgiu G; Piras D; Saderi L; Muroni MR; Carru C; Arru C; Mocci C; Pinna G; Barbara R; Cossu-Rocca P; De Miglio MR
Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052843
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
Ethier JL; Ocaña A; Rodríguez Lescure A; Ruíz A; Alba E; Calvo L; Ruíz-Borrego M; Santaballa A; Rodríguez CA; Crespo C; Ramos M; Gracia Marco J; Lluch A; Álvarez I; Casas M; Sánchez-Aragó M; Carrasco E; Caballero R; Amir E; Martin M
Eur J Cancer; 2018 May; 94():199-205. PubMed ID: 29573665
[TBL] [Abstract][Full Text] [Related]
20. Is It Time to Consider the Androgen Receptor as a Therapeutic Target in Breast Cancer?
Forooshani MK; Scarpitta R; Fanelli GN; Miccoli M; Naccarato AG; Scatena C
Anticancer Agents Med Chem; 2022; 22(4):775-786. PubMed ID: 34852747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
